Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: LENZ

LENZ Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for LENZ. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-4.13

LENZ Therapeutics, Inc. (NASDAQ: LENZ) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 04:34 UTC.

What LENZ Therapeutics, Inc. does

The company is a commercial pharmaceutical firm focused on developing and commercializing therapies for vision improvement. In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, a once-daily eye drop for treating presbyopia, which the company began commercializing in the U.S. in August 2025 through direct-to-eye care professional sales and retail pharmacy distribution. VIZZ works through a pupil-selective mechanism that constricts the iris to improve near vision for up to ten hours without causing myopic shift or requiring ciliary muscle stimulation.

Summarized from LENZ Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-4.13

Charts

Charts are in the appInteractive charts for LENZ are available in Oxford Ledge.
Open LENZ in Oxford Ledge →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-15
Most recent filed transactions — June 2026:
  • 2026-06-15DirectorStock Option (right to buy)Award22,100—
  • 2026-06-15DirectorStock Option (right to buy)Award22,100—
  • 2026-06-15DirectorStock Option (right to buy)Award22,100—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does LENZ Therapeutics, Inc. do?

The company is a commercial pharmaceutical firm focused on developing and commercializing therapies for vision improvement.

When did LENZ last file with the SEC?

LENZ Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 04:34 UTC. This page is also available as JSON at /api/data?ticker=LENZ and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for LENZ and 5,000+ tickers.

Create a free account — keep LENZ
For your agent
GET /api/data?ticker=LENZ

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt